DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
10647
CJM-112
2
Unknown
Investigational
Unknown
Unknown
Multiple Myeloma; Psoriasis; Acne Vulgaris; Asthma; Hidradenitis Suppurativa
Interleukin 17A binding agent
CJM-112
×
Maximum Phase:
2
First Approval:
None
UNII:
F7B2Y24NOE
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ALAGEBRIUM
2
Small molecule
Investigational
Unknown
Unknown
Heart Failure, Diastolic
Unknown
ALAGEBRIUM
×
Maximum Phase:
2
First Approval:
None
UNII:
DGH49JXB1F
Molecule Type:
Small molecule
Molecular Formula:
C13H14NOS+
Molecular Weight:
232.33
AlogP:
2.54
PSA:
20.95
HBD:
0.0
HBA:
#RotB:
3.0
Source:
PAGOCLONE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
GABA-A receptor; anion channel positive allosteric modulator
PAGOCLONE
×
Maximum Phase:
2
First Approval:
None
UNII:
38VAG2SA33
Molecule Type:
Small molecule
Molecular Formula:
C23H22ClN3O2
Molecular Weight:
407.9
AlogP:
5.38
PSA:
63.16
HBD:
0.0
HBA:
#RotB:
6.0
Source:
RADALBUVIR
2
Small molecule
Investigational
Unknown
Unknown
Hepatitis C; Hepatitis C, Chronic
Hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitor
RADALBUVIR
×
Maximum Phase:
2
First Approval:
None
UNII:
273K4V0SPC
Molecule Type:
Small molecule
Molecular Formula:
C30H41NO6S
Molecular Weight:
543.73
AlogP:
5.4
PSA:
96.3
HBD:
2.0
HBA:
#RotB:
7.0
Source:
LIVOLETIDE
2
Protein
Investigational
Unknown
Unknown
Diabetes Mellitus, Type 2; Prader-Willi Syndrome
Unknown
LIVOLETIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
9VHD7J6363
Molecule Type:
Protein
Molecular Formula:
C40H63N15O13
Molecular Weight:
962.04
AlogP:
-6.34
PSA:
458.3
HBD:
15.0
HBA:
#RotB:
17.0
Source:
HPC, CORD BLOOD
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
HPC, CORD BLOOD
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
VIS-410
2
Unknown
Investigational
Unknown
Unknown
Influenza, Human
Hemagglutinin inhibitor
VIS-410
×
Maximum Phase:
2
First Approval:
None
UNII:
14WE3Z92C4
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
INDUSATUMAB VEDOTIN
2
Antibody
Investigational
Unknown
Unknown
Neoplasms; Stomach Neoplasms
Heat-stable enterotoxin receptor binding agent
INDUSATUMAB VEDOTIN
×
Maximum Phase:
2
First Approval:
None
UNII:
3F0FR4W3H8
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SOTRASTAURIN
2
Small molecule
Investigational
Unknown
Unknown
Lymphoma; Lymphoma, Large B-Cell, Diffuse; Colitis, Ulcerative; Psoriasis; Uveitis, Posterior
Protein kinase C (PKC) inhibitor
SOTRASTAURIN
×
Maximum Phase:
2
First Approval:
None
UNII:
7I279E1NZ8
Molecule Type:
Small molecule
Molecular Formula:
C25H22N6O2
Molecular Weight:
438.49
AlogP:
2.43
PSA:
94.22
HBD:
2.0
HBA:
#RotB:
3.0
Source:
TALACOTUZUMAB
2
Antibody
Investigational
Unknown
Unknown
Lupus Erythematosus, Systemic; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes
Interleukin-3 receptor subunit alpha binding agent
TALACOTUZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
X8JR0I7JE1
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
11C-CARFENTANIL
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
11C-CARFENTANIL
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
STG-001
2
Small molecule
Investigational
Unknown
Unknown
Stargardt Disease
Unknown
STG-001
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C14H10F6N2O2
Molecular Weight:
352.23
AlogP:
4.06
PSA:
55.12
HBD:
1.0
HBA:
#RotB:
4.0
Source:
ELX-02
2
Unknown
Investigational
Unknown
Unknown
Genetic Diseases, Inborn; Kidney Diseases; Cystic Fibrosis; Cystinosis
80S Ribosome modulator
ELX-02
×
Maximum Phase:
2
First Approval:
None
UNII:
TP732M43NA
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CHF-6001
2
Small molecule
Investigational
Unknown
Unknown
Asthma; Pulmonary Disease, Chronic Obstructive
Phosphodiesterase 4 inhibitor
CHF-6001
×
Maximum Phase:
2
First Approval:
None
UNII:
0984EU6E2F
Molecule Type:
Small molecule
Molecular Formula:
C30H30Cl2F2N2O8S
Molecular Weight:
687.54
AlogP:
6.32
PSA:
127.1
HBD:
1.0
HBA:
#RotB:
15.0
Source:
TAS-117
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms
Serine/threonine-protein kinase AKT negative allosteric modulator
TAS-117
×
Maximum Phase:
2
First Approval:
None
UNII:
QI52W1ZIIB
Molecule Type:
Small molecule
Molecular Formula:
C26H24N4O2
Molecular Weight:
424.5
AlogP:
4.33
PSA:
86.19
HBD:
2.0
HBA:
#RotB:
3.0
Source:
REFAMETINIB
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms; Biliary Tract Neoplasms; Carcinoma, Hepatocellular
Dual specificity mitogen-activated protein kinase kinase 1 inhibitor
REFAMETINIB
×
Maximum Phase:
2
First Approval:
None
UNII:
JPX07AFM0N
Molecule Type:
Small molecule
Molecular Formula:
C19H20F3IN2O5S
Molecular Weight:
572.34
AlogP:
3.48
PSA:
107.89
HBD:
4.0
HBA:
#RotB:
9.0
Source:
BALAPIRAVIR
2
Small molecule
Investigational
Unknown
Unknown
Severe Dengue; Hepatitis C, Chronic
Hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitor
BALAPIRAVIR
×
Maximum Phase:
2
First Approval:
None
UNII:
VOT0LP7I9K
Molecule Type:
Small molecule
Molecular Formula:
C21H30N6O8
Molecular Weight:
494.51
AlogP:
1.7
PSA:
197.8
HBD:
1.0
HBA:
#RotB:
9.0
Source:
MK-2461
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms
Hepatocyte growth factor receptor inhibitor
MK-2461
×
Maximum Phase:
2
First Approval:
None
UNII:
4200RD53XF
Molecule Type:
Small molecule
Molecular Formula:
C24H25N5O5S
Molecular Weight:
495.56
AlogP:
2.15
PSA:
115.65
HBD:
1.0
HBA:
#RotB:
6.0
Source:
AFELETECAN HYDROCHLORIDE
2
Small molecule
Investigational
Unknown
Unknown
Carcinoma, Renal Cell
Unknown
AFELETECAN HYDROCHLORIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
DTJ7VPW43J
Molecule Type:
Small molecule
Molecular Formula:
C45H50ClN7O11S
Molecular Weight:
932.45
AlogP:
2.95
PSA:
237.48
HBD:
6.0
HBA:
#RotB:
13.0
Source:
UK-453,061
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
UK-453,061
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TETRACHLORODECAOXIDE
2
Small molecule
Investigational
Unknown
Unknown
Wounds and Injuries
Unknown
TETRACHLORODECAOXIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
549BT7IE1Q
Molecule Type:
Small molecule
Molecular Formula:
H2Cl4O11-4
Molecular Weight:
319.82
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
CORN STARCH
2
Oligosaccharide
Investigational
Unknown
Unknown
Unknown
Unknown
CORN STARCH
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Oligosaccharide
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ARHALOFENATE
2
Small molecule
Investigational
Unknown
Unknown
Diabetes Mellitus, Type 2; Gout
Peroxisome proliferator-activated receptor gamma modulator
ARHALOFENATE
×
Maximum Phase:
2
First Approval:
None
UNII:
1P01UJR9X1
Molecule Type:
Small molecule
Molecular Formula:
C19H17ClF3NO4
Molecular Weight:
415.8
AlogP:
4.16
PSA:
64.63
HBD:
1.0
HBA:
#RotB:
7.0
Source:
MK-8998
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
MK-8998
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LY545694
2
Small molecule
Investigational
Unknown
Unknown
Diabetic Neuropathies
Metabotropic glutamate receptor 5 antagonist
LY545694
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
INCB-086550
2
Unknown
Investigational
Unknown
Unknown
Neoplasms
Unknown
INCB-086550
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BELVARAFENIB
2
Small molecule
Investigational
Unknown
Unknown
Melanoma; Neoplasms
RAF serine/threonine protein kinase inhibitor
BELVARAFENIB
×
Maximum Phase:
2
First Approval:
None
UNII:
31M3WLJ3KG
Molecule Type:
Small molecule
Molecular Formula:
C23H16ClFN6OS
Molecular Weight:
478.94
AlogP:
5.92
PSA:
105.82
HBD:
3.0
HBA:
#RotB:
4.0
Source:
EBSELEN
2
Small molecule
Investigational
Unknown
Unknown
Bipolar Disorder; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Hearing Loss; Ototoxicity; Severe Acute Respiratory Syndrome; Meniere Disease
Antioxidant
EBSELEN
×
Maximum Phase:
2
First Approval:
None
UNII:
40X2P7DPGH
Molecule Type:
Small molecule
Molecular Formula:
C13H9NOSe
Molecular Weight:
274.18
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
M281
2
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
M281
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BGC-20-1531
2
Small molecule
Investigational
Unknown
Unknown
Migraine Disorders
Unknown
BGC-20-1531
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C26H23N2NaO6S
Molecular Weight:
514.54
AlogP:
4.66
PSA:
107.73
HBD:
1.0
HBA:
#RotB:
8.0
Source:
FLUPIRTINE
2
Small molecule
Investigational
Unknown
Unknown
Fever; Multiple Sclerosis, Relapsing-Remitting; Pain
Unknown
FLUPIRTINE
×
Maximum Phase:
2
First Approval:
None
UNII:
MOH3ET196H
Molecule Type:
Small molecule
Molecular Formula:
C15H17FN4O2
Molecular Weight:
304.32
AlogP:
2.98
PSA:
89.27
HBD:
3.0
HBA:
#RotB:
5.0
Source:
GLENZOCIMAB
2
Antibody
Investigational
Unknown
Unknown
Ischemic Stroke
Platelet glycoprotein VI (GPVI) inhibitor
GLENZOCIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
58D9BCH9O0
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ALLICIN
2
Small molecule
Investigational
Unknown
Unknown
Lymphoma, Follicular
Unknown
ALLICIN
×
Maximum Phase:
2
First Approval:
None
UNII:
3C39BY17Y6
Molecule Type:
Small molecule
Molecular Formula:
C6H10OS2
Molecular Weight:
162.28
AlogP:
1.76
PSA:
17.07
HBD:
0.0
HBA:
#RotB:
5.0
Source:
IMGATUZUMAB
2
Antibody
Investigational
Unknown
Unknown
Head and Neck Neoplasms; Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms
Epidermal growth factor receptor erbB1 inhibitor
IMGATUZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
V77J4WJF9Z
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CP101
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
CP101
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
1
2
…
154
155
156
157
158
159
160
…
304
305
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA